A Phase 1 Study of MDV3100 in Patients With Castration-Resistant (Hormone-Refractory) Prostate Cancer

Clinical Trial ID NCT00510718

Rank	Title	Journal	Year	PubWeight™‹?›
1	Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study.	Lancet	2010	10.79
2	Circulating tumor cells as biomarkers in prostate cancer.	Clin Cancer Res	2011	2.17
3	Clinical Pharmacokinetic Studies of Enzalutamide.	Clin Pharmacokinet	2015	1.42
4	Long-term Safety and Antitumor Activity in the Phase 1-2 Study of Enzalutamide in Pre- and Post-docetaxel Castration-Resistant Prostate Cancer.	Eur Urol	2015	1.29
5	Circulating tumors cells as biomarkers: progress toward biomarker qualification.	Cancer J	2011	1.25
6	Therapeutic targeting of the prostate cancer microenvironment.	Nat Rev Urol	2010	1.22
7	Novel targeted therapeutics for metastatic castration-resistant prostate cancer.	Cancer Lett	2009	1.04
8	Complete biochemical (prostate-specific antigen) response to sipuleucel-T with enzalutamide in castration-resistant prostate cancer: a case report with implications for future research.	Urology	2013	0.89
9	Enzalutamide as a second generation antiandrogen for treatment of advanced prostate cancer.	Drug Des Devel Ther	2013	0.83
10	Enzalutamide: an evidence-based review of its use in the treatment of prostate cancer.	Core Evid	2013	0.82
11	Therapeutic Rationales, Progresses, Failures, and Future Directions for Advanced Prostate Cancer.	Int J Biol Sci	2016	0.81
12	A multicenter phase I/II study of enzalutamide in Japanese patients with castration-resistant prostate cancer.	Int J Clin Oncol	2016	0.78